To evaluate the effectiveness and safety of Salvianolate injection (SI) in the treatment of acute cerebral infarction (ACI).
Introduction
Stroke, with its high morbidity and mortality, remains an important public health problem. It has been proven that Traditional Chinese Medicine (TCM) is an effective complementary intervention for stroke, especially in the treatment of acute cerebral infarction (ACI). In TCM theories, ACI refers to "apoplexy," majorly due to blood stasis syndrome. Therefore, the therapeutic principle is promoting blood circulation to remove blood stasis of TCM. [1, 2] Recently, Salvianolate injection (SI) combined with Western medicine (WM) is widely used in the treatment of ACI. SI is made of the extraction of Danshen (Radix Salviae miltiorrhizae). Salvianolic acid B in Salvia miltiorrhizae biological activity, one of the highest extract has been confirmed in the experiments in vivo and in vitro has neuroprotective and anti-inflammatory effects. [3] Many systematic reviews regarding SI in the treatment of cerebral infarction, both showing the superiority of SI to control group (CG) in improving the activities daily living function, but none of the articles mentioned any improvement in cognitive ability. [1, 2, 4] In this systematic review, we chose the published, qualified, and well homogeneity clinical studies regarding the combined use of SI for treating ACI to make meta-analysis. In our study, we evaluated the change of activities daily living function and cognitive function, the change of hemorheology indexes, and efficacy and safety of SI.
diagnosis Standard, or the World Health Organization criteria. [5] Diagnoses were validated using computed tomography or magnetic resonance imaging scanning. The course of disease was in 72 hours or shorter, and all participants were experiencing the first onset of ACI. Trials that included patients of any age or sex with ischemic stroke were eligible.
Interventions.
The main interventions include SI combined with WM versus WM treatments alone. WM treatments included thrombolytic therapy, platelet aggregation, cerebral protection agents, and so on. The drugs could be statins, dextran-40, mannitol, aspirin, citicoline, sodium ozagrel, and so on. No limitation on the doses, treatment courses, and drug manufacturers.
2.1.4. Outcomes. We used different outcomes to evaluate the activities daily living function and cognitive function of the patients with ACI. The primary outcomes were of this metaanalysis were Activities of daily living function evaluation computed by National Institute of Health Stroke Scale (NHISS), Barthel Index (BI), activities of daily living (ADL), and distribution of the modified Rankin Scale (mRS) The secondary outcomes of this meta-analysis were hemorheology indexes, including plasma viscosity (PV), content of fibrinogen (FIB), and C-reactive protein (CRP)/high-sensitivity Creactive protein (hs-CRP), and adverse drug reactions (ADRs)/ adverse drug events (ADEs).
Efficacy criteria.
Neural function defect scale (NDS) changes after treatment or nerve function defect improved efficiently. Total clinical effective rate (%) = (number of recovered patients + number of patients with significant progress + number of patients with progress)/total number Â 100%. [6] Recovered was determined when the neurological deficit score decreased from 91% to 100%. Significant progress was determined when the neurological deficit score decreased by between 46% and 90%. Progress was determined when the neurological deficit score decreased by between 18% and 45%. No change or worsen was determined when the functional deficit score decreased by <17%. 
Exclusion criteria

Searching strategies
A general search of published literature was conducted in the electronic databases from inception to July 31, 2017. Studies were first identified for inclusion by examining the title and abstract of each record. We then sought the full text version of suitable articles before applying the inclusion criteria. Two independent investigators (YN, YX) performed a systematic literature search in including PubMed, the Cochrane Center Controlled Trials Register, EMBASE, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wanfang Database without any restrictions to languages and calendar date. In the Chinese databases, the terms"Dan shen duo fen suan yan Zhu she ye" and "Zhu she yong Dan Shen Duo Fen suan yan," and "Dan shen duo fen suan yan Zhu she ji" were used as subject terms for the initial search, and then "Ji Xing Que Xue Xing Cu Zhong" or"Que Xue Xing Zhong Feng" or "Que Xue Xing Nao Xue Guan Bing" or "Nao Geng Si" or "Nao Geng Se" was used to search again among above results. In English databases, the Mesh terms of "Salvianolate injection," and "Dan Shen Duo Fen suan yan injection" were used as subject words for the initial search, and "acute ischemic stroke," and "acute cerebral infarction" were used for further retrieval. Effort was made to include all available studies, including contact with authors. We also searched references lists of retrieved articles, conference abstracts, and trials registries for additional studies.
The search strategy in PubMed is given below.
( (5) 2.4. Data synthesis and quality assessment Ethical approval was unnecessary for this meta-analysis, because our meta-analysis was the procedure that just gathered the experimental data in each RCT without any leak of patient information. All the meta-analyses data used Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) to synthesize and analyze. [7] For outcomes, this meta-analysis chose relative risk (RR) to evaluate dichotomous outcomes, whereas using standardized mean difference ± mean difference to assess continuous variables. Each outcome numerical value was presented with 95% confidence intervals as well. Heterogeneity between RCTs was analyzed by chi-square test and estimated by I 2 . Metaanalyses were calculated by random-effects model. In addition, We used the Cochrane Risk of bias summary tool to conduct a quality evaluation on the included RCTs, whose items contains sequence generation (selection bias), allocation concealment (selection bias), blinding of patients and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other sources of bias. [8] The RCTs were rated into "high," "unclear," or "low." "High" referred to incorrect random methods, no allocation concealment, or no blinding. "Unclear" referred to no description in the text with which to assess bias. "Low" referred to correct random methods, appropriate blinding without being violated through implementation, and detailed description in the RCT.
Results
Searching result
A total of 176 articles were retrieved from the databases listed above. After reading the full text, by removing case studies and articles that did not meet the inclusion criteria, 39 RCTs were included (Table 1 ). All RCTs were conducted in China NanZhu et al. Medicine (2018) 97: 47 Medicine and published in full ( Fig. 1 ; flow chart of literature search). The 39 RCTs included 4516 cases, among which 2273 cases were in the EGs, whereas 2243 in the CGs. In the all of the RCTs, the maximum sample size was 300 cases, whereas the minimum sample size was 38 cases. All patients in the RCTs were diagnosed as having ACI by the diagnostic standard. As for intervention, the EG was SI and WM and the CG was WM. WM included aspirin, defibrase, and so on. The daily dose of SI ranged from 100 to 300 mg. The duration of treatments ranged from 7 to 70 days.
Quality of the included studies
We used the Cochrane Risk of bias summary Tool to conduct a quality evaluation on the included RCTs ( Fig. 2 ; risk of bias summary). The results showed that 18 RCTs [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] described the method to generate the allocation sequence, among which 12 RCTs [9] [10] [11] [13] [14] [15] [16] [17] 19, 22, 23, 26] used the random figure table, 1 RCT [21] used the random queue insertion, and 1 RCT [24] used the random draw envelope principle. Four RTCs [12, 18, 20, 25] were divided into groups by different therapies. And the remaining RCTs were randomly divided into 2 groups. All of RCTs did not provide information on blinding. Actually the overall quality of the included RCTs was generally not high.
Outcomes
Some of the RCTs were divided into subgroups caused by the differences in the course. The results of each subgroup were analyzed as follows. There were 21 studies, [9, [15] [16] [17] [18] [21] [22] [23] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] which mentioned the comparison of activities daily living function evaluation scores between SI + WM and WM. Different Outcomes were used, including NHISS, BI, ADL, and mRS. There were 19 trials, [9, [15] [16] [17] [18] [20] [21] [22] [23] 26, [29] [30] [31] [32] [33] [34] [35] [36] [37] which mentioned the change of NHISS scores. And the meta-analysis showed that the effect of EG was better than CG in improving NHISS scores (P < .00001). Totally 10 trials [9,15-17,23,28,30,31,33,34,] mentioned the change of BI scores. Meta-analysis results indicated a statistically significant difference between EG and CG (P < .00001). There were 7 trials, [20] [21] [22] 27, 29, 32, 35] which mentioned the change of ADL scores. And the meta-analysis showed that the effect of EG was better than CG in improving ADL scores (P < .00001). From the results of different dose subgroups analysis, the activities daily living function evaluation scores of 2 subgroups was statistically significant difference in MoCA scores between the groups in the 100 mg subgroups. Four trials [16, 31, 33, 34] mentioned the change of mRS scores (Table 2 ). There was no significant difference in mRS scores between the 2 groups (P = .008).
Cognitive function evaluation scores.
There were 5 studies, [16, [33] [34] [35] 38] which mentioned the comparison of cognitive function evaluation scores between SI + WM and WM. Different Outcomes were used, including MoCA and MMSE scores. There were 4 trials, [16, 33, 34, 38] which mentioned the change of MoCA scores. The meta-analysis showed that the effect of EG was better than CG in improving MoCA scores (P = .001). From the results of 100 mg subgroups analysis, showed statistically significant difference between 2 groups (P = .0011). There was no significant difference in MoCA scores between the 1 groups in the 200 mg subgroups (P = .069).
There were 5 trials, [16, [33] [34] [35] 38] which mentioned the change of MMSE scores. And the meta-analysis showed that the effect of EG was better than CG in improving MMSE scores (P < .00001). (Table 3 ) There was no significant difference in MMSE scores between the 100 mg subgroups (P = .001) and 200 mg subgroups (P < .00001).
Hemorheology indexes.
In all, 14 RCTs [10,11,13,17-20, 25,28,30,32,36,41,42] mentioned hemorheology indexes, including PV, whole blood high-shear viscosity (WBHSV), whole blood low-shear viscosity (WBLSV), and content of FIB. More details are presented in Table 4 .
(1) PV: There were 7 studies, [10, 19, 25, 30, 36, 41, 42] which referred to PV. The result of meta-analysis signified that the effect of EG was better than CG in decreasing PV (P < .00001). (2) WBHSV: There were 7 studies, [10, 11, 13, 18, 19, 25, 30] which mentioned the WBHSV. Meta-analysis result indicated that there was a statistically significant difference between the EG and CG groups (P < .00001). (3) WBLSV: There were 7 studies, [10, 11, 13, 18, 20, 25, 30] which mentioned the WBLSV. Meta-analysis result indicated that there was a statistically significant difference between the EG and CG groups (P < .00001). (4) FIB: There were 6 studies, [10, 13, 17, 28, 32, 36] which mentioned the content of FIB. Meta-analysis result indicated that there was a statistically significant difference between the EG and CG groups (P < 0.00001).
hs-CRP and CRP.
There were 3 studies, [15, 25, 30] which mentioned the change of hs-CRP, and 9 studies Meta-analysis result showed that both of them have statistically significant difference between the EG and CG groups (P < .00001) ( Table 5 ).
Total clinical effective rate
A total of 21 studies [11] [12] [13] 15, 17, 20, [23] [24] [25] 27, 29, 36, 37, [39] [40] [41] [42] [43] [44] [45] [46] reported the total effective rate. Meta-analysis results indicated a statistically significant difference between EG and CG. The statistical difference between the 2 groups was significant (P < .00001) (shown in Fig. 3) . Figure 4 displayed a funnel plot on publication bias for clinical total effective rate, which was depicted by RR values and the standard error of RR values. The funnel plot presented a general symmetry, and the studies included concentrated upon the upper part of it.
Neural function defect scale
Totally 8 studies [10, 12, 14, 19, 27, 40, 46, 47] reported the NDS. Metaanalysis result manifested that there was a statistically significant difference between the 2 groups, and the combination of SI and WM could achieve a better effect on improving the NDS (P < .00001) (shown in Fig. 5 ).
Safety
A total of 10 studies [16, 18, 21, 24, 25, 27, 34, 36, 37, 46] mentioned obvious ADRs/ADEs, during the implementation of trials, ADRs including headache, dizziness, gastrointestinal reaction, and so on. The incidence of adverse effects was 7.81% (40/512). And the incidence of adverse effects was 9.57% (43/449) No severe adverse events were reported. Only 1 study indicated that there were no ADRs/ADEs in both groups. There was no significant difference about ADRs/ADEs between the EG and CG (P = .73) (shown in Fig. 6 ).
Discussion
According to the results of this meta-analysis, we found that compared with WM therapies, SI combined with WM demonstrated a potential beneficial effect for ACI patients. A total of 39 randomized trials including 4516 participants were included. In addition, the methodological quality of all trials was limited. SI can make a more noticeable impact for ACI patients, which was embodied in the following aspects: first of all, a combination use of SI and WM has a notable performance on improving clinical total effective rate, perfecting neurologic deficiency, improving activities daily living function, and cognition disorders. There was no significant difference in mRS scores between the EG and the CG. Secondly, the combined use of Salvianolate and WM therapy can improve the hemorheology indexes, including PV, WBHSV, WBLSV, and FIB levels. And there were statistically significant differences between the 2 groups in improving the hs-CRP and CRP levels. In terms of ADRs/ADEs, there was no definite conclusion about safety between 2 groups. In a summary, the results of subgroup analysis showed that high dose neither significantly improve the efficacy nor reduce the risk about safety. That means the course of SI should be in strict accordance with the drug instructions.
At present, there is a lack of systemic reviews about comparing SI + WM and WM in evaluate the effectiveness and safety of SI on motor and cognitive function of patients with ACI. There were 2 related systematic reviews in database, which published in 2013 [4] and 2017. [48] In Lu et al's study, [4] the evaluation indexes including the change of activities daily living function evaluation and ADRs/ADEs, but no more exact figures were mentioned. Five RCTs were included in the study, but 2 RCTs of them [11, 49] had the same authors and similar study phase. The data in 2 RCTs maybe have some overlap. Therefore, these 2 systematic reviews can be considered from the same test. That means the experimental design is not rigorous. In Zeng et al's [48] study the experimental design is not rigorous, too. The objective of the study is to evaluate the effectiveness and safety of SI on motor and cognitive function of patients with ACI. But in fact the change of cognitive function was not included in evaluation indexes.
This study shows that SI has the function of improving activities of daily living function and cognitive function, and promoting the recovery of nerve function, In our inclusion criteria, the EG only used SI combined with WM, the CG used WM single, just for avoiding other TCM preparations possible interference on the results. And the RCTs' quality assessment was conducted by the Cochrane Risk of Bias Assessment Tool. Our study not only updated the latest RCTs but also analyzed the differences of high dose and low dose.
No severe adverse events were reported. There was no significant difference about ADRs/ADEs between the EG and Table 2 Meta CG = control group, EG = experimental group, FIB = fibrinogen, PV = plasma viscosity, WBHSV = whole blood high-shear viscosity, WBLSV = whole blood low-shear viscosity (mPa · s). CG. Therefore, the clinical usage of SI should be in strict accordance with the instructions, to avoid the occurrence of compatibility and ADRs.
Study or Subgroup
Limitations
This study has several limitations. First, the review included a total of 39 RCTs; however, the overall quality of the included RCTs was general, and they lacked of large-scale RCTs. Totally 17 included studies mentioned "random" in RCTs, but none of them makes a detailed description about how to generate random sequence, conceal allocation, or whether carried out blinding, which may bring about certain bias for assessment and influence the grade of evidence. Although Egger test and Begg test showed that there was no publication bias in this study, the included RCTs concentrated upon the upper part of funnel plot. It revealed that our meta-analysis may lack RCTs whose sample size was quality. Second, the systematic review included only published studies in the database, with no the relevant gray literature, which possibly cause a selection bias in the literature. And the included RCTs were performed in Chinese patients; therefore, it is unclear whether the conclusions of our study apply to other populations. Third, the treatment course of included RCTs was short and clinicians did not conduct follow-up visit. Despite the above limitations, our study provided a complete evaluation for the effectiveness and safety of SI on treating cerebral infarction.
Conclusion
To sum up, our study evaluated the effectiveness and safety of SI in the treatment of ACI. We found that SI could improve the motor and cognitive function of patients with ACI. In general, we draw a conclusion that SI had a positive effect on treating cerebral infarction, improving motor and cognitive function, but more multicenter and high-quality RCTs should be implemented in the future to support evidence. 
